Articles

Patients diagnosed with cancer today are considered to be genuine partners in all major treatment decisions. Yet, how well do they understand the nature and goals of genetic testing that might be recommended as part of the management of their disease?

A Failure to Communicate: Patients Misunderstand Cancer Genetic Testing

Despite all we have learned about the importance of sensitizing EGFR mutations in defining the management of advanced NSCLC, our education regarding the relevance of this molecular target in optimizing clinical outcomes continues.

EGFR's Evolution: New Insights Refine Role of Mutation in NSCLC

Maurie Markman, MD, asks who should decide whether it is ethically valid to consider off-label treatment in a patient with a very serious medical illness.


Who Should Decide? Trying a Novel Strategy in a Desperate Situation

In the absence of a phase III randomized trial, what constitutes sufficient evidence to justify use of a treatment, particularly a nontraditional treatment or one that challenges common practice?

Cancer Treatment Centers of America

Latest from Cancer Treatment Centers of America

New content coming soon, please check back later.